Xenon Pharmaceuticals (XENE) Change in Accured Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Change in Accured Expenses data on file, last reported at -$1.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 52.39% year-over-year to -$1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (down 23.27% YoY) and the FY2025 annual result came in at $5.5 million, down 35.4% from the prior year.
• Change in Accured Expenses retreated to -$1.8 million in Q1 2026 per XENE's latest filing, from $2.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $9.2 million in Q2 2024 and bottomed at -$5.8 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $2.1 million (2022), against an average of $1.4 million.
• Peak annual rise in Change in Accured Expenses reached 270.75% in 2024, while the deepest fall reached 744.78% in 2024.
• Tracing XENE's Change in Accured Expenses over 5 years: stood at $6.0 million in 2022, then plunged by 61.76% to $2.3 million in 2023, then soared by 270.75% to $8.5 million in 2024, then slumped by 72.42% to $2.4 million in 2025, then sank by 176.54% to -$1.8 million in 2026.
• Per Business Quant, the three latest XENE Change in Accured Expenses figures stand at -$1.8 million (Q1 2026), $2.4 million (Q4 2025), and $6.1 million (Q3 2025).

Peer Comparison